NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.

Lumito AB (publ) (”Lumito” or the ”Company”) has completed the issue of units, consisting of warrants of series TO5 and TO6 with preferential rights for existing shareholders (the "Issue"), which the board of directors resolved on November 10, 2023 (changes to the terms and conditions for the Issue were resolved and announced on November 17, 2023). The outcome concludes that 3,810,412 units have been subscribed through the use of unit rights, corresponding to approximately 88.6 percent of the Issue. Additionally, the Issue has been fully subscribed multiple times without the support of unit rights. Thus, the Issue has been fully subscribed. The Issue will provide the Company with approximately SEK 43 thousand before issue costs.

Comment from Mattias Lundin, CEO
I am very pleased and grateful for the interest our shareholders have shown in this issue of warrants, and the fact that there has also been a great interest in participating even without priority is of course very encouraging. We look forward to next year and our plans for the launch of SCIZYS where the capital will be of great use.

Final outcome
The subscription period in the Issue ended December 13, 2023. The final outcome shows that a total of 3,810,412 units have been subscribed for using unit rights, corresponding to 88.6 percent of the Issue. Additionally, the Issue has been fully subscribed multiple times without the support of unit rights. Thus, the Issue has been fully subscribed. Consequently, 4,300,781 units have been allotted to subscribers, corresponding to 100 percent of the Issue. Each unit consists of four (4) warrants of series TO5 and four (4) warrants of series TO6. In total, 4,300,781 units were subscribed, corresponding to 17,203,124 warrants of series TO5 and 17,203,124 warrants of series TO6.

Upon full exercise of all warrants of series TO5 issued in the Issue, the Company may be provided with an additional capital injection of up to approximately SEK 20.6 million. Upon full exercise of all warrants of series TO6 issued in the Issue, the Company may be provided with an additional capital injection of up to approximately SEK 24.1 million.

Allotment of units subscribed without the support of unit rights
Allotment of units subscribed for without the support of unit rights has taken place in accordance with what is stated in the prospectus that the Company published on November 27, 2023, due to the Issue (the "Prospectus"). Notification of such allocation is announced separately through settlement notes. Nominee-registered shareholders receive notification of allotment in accordance with instructions from the respective nominee.

Trading with paid subscribed units (”BTU”)
Trading with BTU takes place until BTU is converted to warrants of series TO5 and warrants of series TO6, which will be converted upon registration of the Issue at the Swedish Companies Registration Office, expected to take place during week 52, 2023.

Shares, share capital and dilution
If all warrants of series TO5 (comprising warrants of series TO5 issued within the scope of the Issue as well as warrants of series TO5 previously issued according to public announcements from the Company) are fully exercised for subscription of new shares in the Company, the number of shares in the Company will increase with an additional 34,406,248 shares, from 206,437,488 shares to 240,843,736 shares, and the share capital will increase with an additional SEK 860,156.20, from SEK 5,160,937.20 to SEK 6,021,093.40, corresponding to a dilution of 14.3 percent in the number of shares.

If all warrants of series TO6 (comprising warrants of series TO6 issued within the scope of the Issue as well as warrants of series TO6 previously issued according to public announcements from the Company) are fully exercised for subscription of new shares in the Company, the number of shares in the Company will increase with an additional 34,406,248 shares, from 240,843,736 shares to 275,249,984 shares, and the share capital will increase with an additional SEK 860,156.20, from SEK 6,021,093.40 to SEK 6,881,249.60, corresponding to a dilution of 12.5 percent in the number of shares.

Warrants of series TO5

• Each warrant of series TO5 entitles the holder to subscribe for one (1) new share in the Company. The subscription price for shares subscribed for using the warrants of series TO5 is 70 percent of the volume-weighted average price of the Company's share during the period from May 13, 2024 to May 24, 2024, however, not less than the share's quotient value (currently SEK 0.025) and not more than SEK 1.20.
• The warrants of series TO5 can be exercised for the subscription of new shares during the period from May 27, 2024 to June 10, 2024.
• Upon full subscription in the Issue and full exercise of all warrants of series TO5 within the scope of the offered units, the Company may receive a maximum of approximately SEK 41.3 million before transaction costs.
• The warrants of series TO5 are intended to be admitted to trading on NGM Nordic SME after final registration with the Swedish Companies Registration Office.
• Full terms and conditions for the warrants of series TO5 are available on the Company's website, www.lumito.se.

Warrants of series TO6

• Each warrant of series TO6 entitles the holder to subscribe for one (1) new share in the Company. The subscription price for shares subscribed for using the series TO6 warrants is 70 percent of the volume-weighted average price of the Company's share during the period from October 21, 2024 to November 1, 2024, however, not less than the share's quotient value (currently SEK 0.025) and not more than SEK 1.40.
• The warrants of series TO6 can be exercised for the subscription of new shares during the period from November 4, 2024 to November 15, 2024.
• Upon full subscription in the Issue and full exercise of all warrants of series TO6 within the scope of the offered units, the Company may receive a maximum of approximately SEK 48.2 million before transaction costs.
• The warrants of series TO6 are intended to be admitted to trading on NGM Nordic SME after final registration with the Swedish Companies Registration Office.
• Full terms and conditions for the warrants of series TO6 are available on the Company's website, www.lumito.se.

Advisers
Mangold Fondkommission AB is financial adviser and Advokatfirman Lindahl KB is legal advisor Lumito in connection with the Issue.

For further information, please contact:

Mattias Lundin, CEO Lumito
E-mail: ml@lumito.se
Ph: +46 76 868 45 09 

This information is information that Lumito is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-12-15 08:30 CET.

Lumito

Lumito specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Important Information
Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in Lumito in any jurisdiction, either from Lumito or from anyone else. This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. A prospectus regarding the Issue has been prepared by the Company and published on the Company’s website after the prospectus was reviewed and approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) on November 27, 2023.

This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 ("Securities Act"), and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.
 
Forward-looking statements
This press release contains forward-looking statements related to the Company’s intentions, estimates or expectations with regard to the Company’s future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “will,” “may,” “implies,” “should,” “could” and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or NGM Nordic SME Rulebook for Issuers of Shares.

Attachments
Lumitos issue of warrants is fully subscribed multiple times